Drugs / Novel CAR-T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04191941 | Sep 2019 → Aug 2021 | B-cell acute lymphoblastic leukemia, plasma cell myeloma | Timmune Biotech Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novel CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04191941 ↗ |
| Modality | Cell therapy | “Novel CAR-T cell therapy” NCT04191941 ↗ |
| Route | Intravenous | “Novel CAR-T cells will be administered intravenously” NCT04191941 ↗ |